María Talegón

547 total citations
17 papers, 408 citations indexed

About

María Talegón is a scholar working on Immunology, Oncology and Pharmacology. According to data from OpenAlex, María Talegón has authored 17 papers receiving a total of 408 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Immunology, 6 papers in Oncology and 6 papers in Pharmacology. Recurrent topics in María Talegón's work include Psoriasis: Treatment and Pathogenesis (7 papers), Pharmacogenetics and Drug Metabolism (6 papers) and Drug Transport and Resistance Mechanisms (4 papers). María Talegón is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (7 papers), Pharmacogenetics and Drug Metabolism (6 papers) and Drug Transport and Resistance Mechanisms (4 papers). María Talegón collaborates with scholars based in Spain and United States. María Talegón's co-authors include Francisco Abad‐Santos, Teresa Cabaleiro, Manuel Román, Dolores Ochoa, Rocío Prieto‐Pérez, E. Daudén, Carmen Belmonte, Miriam Saiz‐Rodríguez, G. Solano‐López and María C. Ovejero‐Benito and has published in prestigious journals such as Clinical Pharmacology & Therapeutics, Drug Metabolism and Disposition and Clinical Therapeutics.

In The Last Decade

María Talegón

17 papers receiving 401 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
María Talegón Spain 15 164 126 78 76 68 17 408
Patrick Mayo Canada 12 58 0.4× 79 0.6× 48 0.6× 60 0.8× 16 0.2× 26 441
Kyoko Matsuguma Japan 12 39 0.2× 55 0.4× 64 0.8× 76 1.0× 36 0.5× 16 636
Ingrid Fricke-Galindo Mexico 14 90 0.5× 181 1.4× 127 1.6× 130 1.7× 11 0.2× 41 720
Muradiye Nacak Türkiye 13 34 0.2× 203 1.6× 94 1.2× 103 1.4× 20 0.3× 29 598
M Iappelli Italy 15 63 0.4× 47 0.4× 147 1.9× 89 1.2× 8 0.1× 41 810
Habib Hasannejad Japan 6 49 0.3× 42 0.3× 24 0.3× 213 2.8× 59 0.9× 7 437
Toru Usui Japan 15 55 0.3× 204 1.6× 98 1.3× 87 1.1× 13 0.2× 27 608
B Kattman United States 9 30 0.2× 126 1.0× 66 0.8× 82 1.1× 7 0.1× 25 676
Melih O. Babaoğlu Türkiye 13 26 0.2× 118 0.9× 58 0.7× 134 1.8× 12 0.2× 43 509
Hervé Le-Louët France 7 44 0.3× 111 0.9× 279 3.6× 64 0.8× 48 0.7× 13 461

Countries citing papers authored by María Talegón

Since Specialization
Citations

This map shows the geographic impact of María Talegón's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by María Talegón with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites María Talegón more than expected).

Fields of papers citing papers by María Talegón

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by María Talegón. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by María Talegón. The network helps show where María Talegón may publish in the future.

Co-authorship network of co-authors of María Talegón

This figure shows the co-authorship network connecting the top 25 collaborators of María Talegón. A scholar is included among the top collaborators of María Talegón based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with María Talegón. María Talegón is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Saiz‐Rodríguez, Miriam, José Luis Caniego, Carmen Belmonte, et al.. (2018). Influence of CYP2C19 Phenotype on the Effect of Clopidogrel in Patients Undergoing a Percutaneous Neurointervention Procedure. Clinical Pharmacology & Therapeutics. 105(3). 661–671. 15 indexed citations
2.
Saiz‐Rodríguez, Miriam, Carmen Belmonte, Nieves Derqui, et al.. (2017). Pharmacogenetics of Trazodone in Healthy Volunteers: Association with Pharmacokinetics, Pharmacodynamics and Safety. Pharmacogenomics. 18(16). 1491–1502. 14 indexed citations
3.
Saiz‐Rodríguez, Miriam, Carmen Belmonte, Manuel Román, et al.. (2017). Effect of Polymorphisms on the Pharmacokinetics, Pharmacodynamics and Safety of Sertraline in Healthy Volunteers. Basic & Clinical Pharmacology & Toxicology. 122(5). 501–511. 52 indexed citations
4.
Belmonte, Carmen, Manuel Román, Miriam Saiz‐Rodríguez, et al.. (2017). Influence of CYP2D6 , CYP3A4 , CYP3A5 and abcb1 Polymorphisms in Pharmacokinetics and Safety of Ariprazole in Healthy Volunteers. Clinical Therapeutics. 39(8). e54–e55. 2 indexed citations
5.
Saiz‐Rodríguez, Miriam, Carmen Belmonte, Teresa Cabaleiro, et al.. (2017). ABCB1 C3435T Polymorphism Affects In Different Ways The Pharmacokinetics of Antipsychotics and Antidepressants. Clinical Therapeutics. 39(8). e36–e36. 2 indexed citations
6.
Ovejero‐Benito, María C., Rocío Prieto‐Pérez, Mar Llamas‐Velasco, et al.. (2017). Polymorphisms Associated with Etanercept Response in Moderate-To-Severe Plaque Psoriasis. Pharmacogenomics. 18(7). 631–638. 24 indexed citations
7.
Ovejero‐Benito, María C., Rocío Prieto‐Pérez, Mar Llamas‐Velasco, et al.. (2017). Polymorphisms Associated with Adalimumab and Infliximab Response in Moderate-To-Severe Plaque Psoriasis. Pharmacogenomics. 19(1). 7–16. 24 indexed citations
8.
Prieto‐Pérez, Rocío, G. Solano‐López, Teresa Cabaleiro, et al.. (2016). New polymorphisms associated with response to anti-TNF drugs in patients with moderate-to-severe plaque psoriasis. The Pharmacogenomics Journal. 18(1). 70–75. 33 indexed citations
9.
Prieto‐Pérez, Rocío, Mar Llamas‐Velasco, Teresa Cabaleiro, et al.. (2016). Pharmacogenetics of Ustekinumab in Patients with Moderate-to-severe Plaque Psoriasis. Pharmacogenomics. 18(2). 157–164. 22 indexed citations
10.
Belmonte, Carmen, Dolores Ochoa, Manuel Román, et al.. (2016). Evaluation of the Relationship Between Pharmacokinetics and the Safety of Aripiprazole and Its Cardiovascular Effects in Healthy Volunteers. Journal of Clinical Psychopharmacology. 36(6). 608–614. 14 indexed citations
11.
Prieto‐Pérez, Rocío, G. Solano‐López, Teresa Cabaleiro, et al.. (2015). Polymorphisms Associated with Age at Onset in Patients with Moderate-to-Severe Plaque Psoriasis. Journal of Immunology Research. 2015. 1–8. 20 indexed citations
12.
Ochoa, Dolores, Rocío Prieto‐Pérez, Manuel Román, et al.. (2015). Effect of Gender andCYP2C9andCYP2C8Polymorphisms on the Pharmacokinetics of Ibuprofen Enantiomers. Pharmacogenomics. 16(9). 939–948. 28 indexed citations
13.
Prieto‐Pérez, Rocío, G. Solano‐López, Teresa Cabaleiro, et al.. (2015). The Polymorphism Rs763780 in the IL-17F Gene is Associated with Response to Biological Drugs in Patients with Psoriasis. Pharmacogenomics. 16(15). 1723–1731. 41 indexed citations
14.
Román, Manuel, Dolores Ochoa, María Talegón, et al.. (2014). Evaluation of the Relationship Between Polymorphisms inCYP2C19and the Pharmacokinetics of Omeprazole, Pantoprazole and Rabeprazole. Pharmacogenomics. 15(15). 1893–1901. 26 indexed citations
15.
Cabaleiro, Teresa, Manuel Román, Elena Gallo, et al.. (2013). Association between psoriasis and polymorphisms in the TNF, IL12B, and IL23R genes in Spanish patients. European Journal of Dermatology. 23(5). 640–645. 19 indexed citations
16.
Prieto‐Pérez, Rocío, Dolores Ochoa, Teresa Cabaleiro, et al.. (2013). Evaluation of the relationship between polymorphisms inCYP2C8andCYP2C9and the pharmacokinetics of celecoxib. The Journal of Clinical Pharmacology. 53(12). 1261–1267. 28 indexed citations
17.
Cabaleiro, Teresa, Manuel Román, Dolores Ochoa, et al.. (2012). Evaluation of the Relationship between Sex, Polymorphisms in CYP2C8 and CYP2C9, and Pharmacokinetics of Angiotensin Receptor Blockers. Drug Metabolism and Disposition. 41(1). 224–229. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Patrick Mayo Breakdown of academic impact, for papers by Kyoko Matsuguma Breakdown of academic impact, for papers by Ingrid Fricke-Galindo Breakdown of academic impact, for papers by Muradiye Nacak Breakdown of academic impact, for papers by M Iappelli Breakdown of academic impact, for papers by Habib Hasannejad Breakdown of academic impact, for papers by Toru Usui Breakdown of academic impact, for papers by B Kattman Breakdown of academic impact, for papers by Melih O. Babaoğlu Breakdown of academic impact, for papers by Hervé Le-Louët
Rankless by CCL
2026